BioRestorative Therapies, Inc. Common Stock (NV) financials
$2.33+0.87%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $359.7K | $401.0K | $145.8K | $119.8K | $46.0K |
| Gross profit | $335.9K | $372.9K | $145.8K | $119.8K | $46.0K |
| Gross margin | 93.4% | 93.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$15.6M | -$11.6M | -$15.2M | -$19.0M | -$26.3M |
| Net income | -$14.2M | -$9.0M | -$10.4M | -$13.2M | -$44.3M |
| Net margin | −3959.4% | −2239.2% | −7145.2% | −11037.0% | −96311.5% |
| Diluted EPS | $-31.60 | $-23.20 | $-49.40 | $-73.00 | $-746.00 |
| EBITDA | -$15.4M | -$11.4M | -$15.1M | -$18.9M | -$26.2M |
| Operating cash flow | -$10.8M | -$8.2M | -$6.4M | -$5.9M | -$3.3M |
| Free cash flow | -$10.9M | -$8.3M | -$6.6M | -$6.2M | -$3.4M |
| Diluted shares | 0.4M | 0.4M | 0.2M | 0.2M | 0.1M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $1.5M | $547.9K | $884.4K | $1.7M | $21.0M |
| Short-term investments | $1.4M | $10.2M | $10.2M | $13.0M | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $250.0K |
| Total assets | $4.1M | $12.3M | $12.6M | $16.4M | $22.5M |
| Total liabilities | $3.7M | $3.7M | $2.6M | $6.1M | $856.5K |
| Shareholders' equity | $356.7K | $8.5M | $10.0M | $10.3M | $21.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology